Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Ferella L, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P, Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL, Festuccia C.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2411. doi: 10.1007/s00432-019-02980-6.

PMID:
31346710
2.

Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?

Tini P, Nardone V, Pastina P, Marampon F, Sebaste L, Cerase A, Tombolini V, Pirtoli L, Mazzei MA.

Clin Neurol Neurosurg. 2019 Sep;184:105445. doi: 10.1016/j.clineuro.2019.105445. Epub 2019 Jul 15.

PMID:
31325903
3.

Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.

Marampon F, Di Nisio V, Pietrantoni I, Petragnano F, Fasciani I, Scicchitano BM, Ciccarelli C, Gravina GL, Festuccia C, Del Fattore A, Tombolini M, De Felice F, Musio D, Cecconi S, Tini P, Maddalo M, Codenotti S, Fanzani A, Polimeni A, Maggio R, Tombolini V.

Cancer Lett. 2019 Oct 1;461:90-101. doi: 10.1016/j.canlet.2019.07.009. Epub 2019 Jul 17.

PMID:
31325529
4.

Animal models of well-differentiated/dedifferentiated liposarcoma: utility and limitations.

Codenotti S, Mansoury W, Pinardi L, Monti E, Marampon F, Fanzani A.

Onco Targets Ther. 2019 Jul 3;12:5257-5268. doi: 10.2147/OTT.S175710. eCollection 2019. Review.

5.

Parkinson's disease and light: The bright and the Dark sides.

Maggio R, Vaglini F, Rossi M, Fasciani I, Pietrantoni I, Marampon F, Corsini GU, Scarselli M, Millan MJ.

Brain Res Bull. 2019 Aug;150:290-296. doi: 10.1016/j.brainresbull.2019.06.013. Epub 2019 Jun 19. Review.

PMID:
31226407
6.

Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma.

De Felice F, Vetrone L, Bulzonetti N, Caiazzo R, Marampon F, Musio D, Tombolini V.

Med Oncol. 2019 Jun 12;36(8):68. doi: 10.1007/s12032-019-1292-y.

PMID:
31190132
7.

Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study.

De Felice F, Benevento I, Bulzonetti N, Shima B, Rubini F, Marampon F, Musio D, Tombolini V.

Curr Probl Cancer. 2019 May 23. pii: S0147-0272(18)30234-4. doi: 10.1016/j.currproblcancer.2019.04.003. [Epub ahead of print]

PMID:
31146956
8.

Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.

Marampon F, Ciccarelli C, Zani BM.

Int J Mol Sci. 2019 May 23;20(10). pii: E2530. doi: 10.3390/ijms20102530. Review.

9.

Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis.

Ferella L, Limoncin E, Vittorini F, Chalaszczyk A, Sorce C, Grimaldi G, Franzese P, Ruggieri V, Varrassi E, Di Staso M, Gimenez De Lorenzo R, Marampon F, Tombolini V, Masciocchi C, Gravina GL.

Crit Rev Oncol Hematol. 2019 Jul;139:75-82. doi: 10.1016/j.critrevonc.2019.04.012. Epub 2019 Apr 27.

PMID:
31112885
10.

Immune check-point in glioblastoma multiforme.

De Felice F, Pranno N, Marampon F, Musio D, Salducci M, Polimeni A, Tombolini V.

Crit Rev Oncol Hematol. 2019 Jun;138:60-69. doi: 10.1016/j.critrevonc.2019.03.019. Epub 2019 Apr 4. Review.

PMID:
31092387
11.

Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program.

De Felice F, Megiorni F, Pietrantoni I, Tini P, Lessiani G, Mastroiacovo D, Mattana P, Antinozzi C, Di Luigi L, Delle Monache S, Angelucci A, Festuccia C, Fanzani A, Maggio R, Tombolini V, Gravina GL, Marampon F.

Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2669-2680. doi: 10.26355/eurrev_201903_17415.

12.

Successful role of adjuvant radiotherapy in a rare case of tracheal inflammatory myofibroblastic tumor: a case report.

Lisi R, Abate G, D'Urso P, Martinetti MT, Siniscalchi B, Marampon F, Bulzonetti N, Tombolini V.

Tumori. 2019 Mar 22:300891619838333. doi: 10.1177/0300891619838333. [Epub ahead of print]

PMID:
30900517
13.

The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models.

Gravina GL, Mancini A, Colapietro A, Delle Monache S, Sferra R, Vitale F, Cristiano L, Martellucci S, Marampon F, Mattei V, Beirinckx F, Pujuguet P, Saniere L, Lorenzon G, van der Aar E, Festuccia C.

Cancers (Basel). 2019 Mar 13;11(3). pii: E359. doi: 10.3390/cancers11030359.

14.

Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation.

Codenotti S, Faggi F, Ronca R, Chiodelli P, Grillo E, Guescini M, Megiorni F, Marampon F, Fanzani A.

Cancer Lett. 2019 May 1;449:135-144. doi: 10.1016/j.canlet.2019.02.013. Epub 2019 Feb 13.

PMID:
30771426
15.

NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance.

Marampon F, Codenotti S, Megiorni F, Del Fattore A, Camero S, Gravina GL, Festuccia C, Musio D, De Felice F, Nardone V, Santoro AN, Dominici C, Fanzani A, Pirtoli L, Fioravanti A, Tombolini V, Cheleschi S, Tini P.

J Cancer Res Clin Oncol. 2019 Apr;145(4):881-893. doi: 10.1007/s00432-019-02851-0. Epub 2019 Jan 30.

PMID:
30701326
16.

Comparative study of testosterone and vitamin D analogue, elocalcitol, on insulin-controlled signal transduction pathway regulation in human skeletal muscle cells.

Antinozzi C, Marampon F, Sgrò P, Tombolini V, Lenzi A, Crescioli C, Di Luigi L.

J Endocrinol Invest. 2019 Aug;42(8):897-907. doi: 10.1007/s40618-018-0998-6. Epub 2019 Jan 1.

PMID:
30600434
17.

Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Ferella L, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P, Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL, Festuccia C.

J Cancer Res Clin Oncol. 2019 Feb;145(2):393-409. doi: 10.1007/s00432-018-2800-8. Epub 2018 Nov 24. Erratum in: J Cancer Res Clin Oncol. 2019 Sep;145(9):2411.

PMID:
30474756
18.

Radiation effects on male fertility.

De Felice F, Marchetti C, Marampon F, Cascialli G, Muzii L, Tombolini V.

Andrology. 2019 Jan;7(1):2-7. doi: 10.1111/andr.12562. Epub 2018 Nov 9. Review.

PMID:
30411532
19.

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.

Camero S, Ceccarelli S, De Felice F, Marampon F, Mannarino O, Camicia L, Vescarelli E, Pontecorvi P, Pizer B, Shukla R, Schiavetti A, Mollace MG, Pizzuti A, Tombolini V, Marchese C, Megiorni F, Dominici C.

J Cancer Res Clin Oncol. 2019 Jan;145(1):137-152. doi: 10.1007/s00432-018-2774-6. Epub 2018 Oct 24.

20.

Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study.

De Felice F, D'Ambrosio G, Musio D, Iafrate F, Benevento I, Marzo M, Mancini M, Urbano F, Iannitti M, Marampon F, Bulzonetti N, Cortesi E, Tombolini V.

Oncotarget. 2018 Sep 14;9(72):33702-33709. doi: 10.18632/oncotarget.26101. eCollection 2018 Sep 14.

21.

Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.

Codenotti S, Poli M, Asperti M, Zizioli D, Marampon F, Fanzani A.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1717-1730. doi: 10.1007/s00432-018-2699-0. Epub 2018 Jul 3.

PMID:
29971532
22.

Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.

Ciccarelli C, Di Rocco A, Gravina GL, Mauro A, Festuccia C, Del Fattore A, Berardinelli P, De Felice F, Musio D, Bouché M, Tombolini V, Zani BM, Marampon F.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1685-1699. doi: 10.1007/s00432-018-2696-3. Epub 2018 Jun 29.

PMID:
29959569
23.

Cellular and Molecular Mediators of Bone Metastatic Lesions.

Battafarano G, Rossi M, Marampon F, Del Fattore A.

Int J Mol Sci. 2018 Jun 8;19(6). pii: E1709. doi: 10.3390/ijms19061709. Review.

24.

Testosterone-mediated activation of androgenic signalling sustains in vitro the transformed and radioresistant phenotype of rhabdomyosarcoma cell lines.

Giannattasio S, Megiorni F, Di Nisio V, Del Fattore A, Fontanella R, Camero S, Antinozzi C, Festuccia C, Gravina GL, Cecconi S, Dominici C, Di Luigi L, Ciccarelli C, De Cesaris P, Riccioli A, Zani BM, Lenzi A, Pestell RG, Filippini A, Crescioli C, Tombolini V, Marampon F.

J Endocrinol Invest. 2019 Feb;42(2):183-197. doi: 10.1007/s40618-018-0900-6. Epub 2018 May 22.

PMID:
29790086
25.

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, Delle Monache S, Pompili S, Cristiano L, Vetuschi A, Tombolini V, Chen Y, Mehrling T.

J Hematol Oncol. 2018 Mar 14;11(1):38. doi: 10.1186/s13045-018-0587-3.

26.

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Festuccia C, Mancini A, Colapietro A, Gravina GL, Vitale F, Marampon F, Delle Monache S, Pompili S, Cristiano L, Vetuschi A, Tombolini V, Chen Y, Mehrling T.

J Hematol Oncol. 2018 Feb 27;11(1):32. doi: 10.1186/s13045-018-0576-6. Erratum in: J Hematol Oncol. 2018 Mar 14;11(1):38.

27.

Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy.

Gravina GL, Marampon F, Sanità P, Festuccia C, Forcella C, Scarsella L, Jitariuc A, Vetuschi A, Sferra R, Colapietro A, Carosa E, Dolci S, Lenzi A, Jannini EA.

Oncotarget. 2017 Nov 30;8(69):113792-113806. doi: 10.18632/oncotarget.22776. eCollection 2017 Dec 26.

28.

Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.

Gravina GL, Mancini A, Colapietro A, Marampon F, Sferra R, Pompili S, Biordi LA, Iorio R, Flati V, Argueta C, Landesman Y, Kauffman M, Shacham S, Festuccia C.

Oncotarget. 2017 Nov 30;8(67):111225-111245. doi: 10.18632/oncotarget.22760. eCollection 2017 Dec 19.

29.

Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3 receptors.

Fasciani I, Pietrantoni I, Rossi M, Mannoury la Cour C, Aloisi G, Marampon F, Scarselli M, Millan MJ, Maggio R.

Eur J Pharmacol. 2018 Jan 15;819:181-189. doi: 10.1016/j.ejphar.2017.12.002. Epub 2017 Dec 6.

PMID:
29223348
30.

Radiation therapy and serum salivary amylase in head and neck cancer.

De Felice F, Tombolini M, Musella A, Marampon F, Tombolini V, Musio D.

Oncotarget. 2017 Jun 28;8(52):90496-90500. doi: 10.18632/oncotarget.18763. eCollection 2017 Oct 27. Review.

31.

Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.

Megiorni F, Gravina GL, Camero S, Ceccarelli S, Del Fattore A, Desiderio V, Papaccio F, McDowell HP, Shukla R, Pizzuti A, Beirinckx F, Pujuguet P, Saniere L, der Aar EV, Maggio R, De Felice F, Marchese C, Dominici C, Tombolini V, Festuccia C, Marampon F.

J Hematol Oncol. 2017 Oct 6;10(1):161. doi: 10.1186/s13045-017-0530-z.

32.

The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism.

Marampon F, Antinozzi C, Corinaldesi C, Vannelli GB, Sarchielli E, Migliaccio S, Di Luigi L, Lenzi A, Crescioli C.

Endocrine. 2018 Mar;59(3):602-613. doi: 10.1007/s12020-017-1378-2. Epub 2017 Aug 7.

PMID:
28786077
33.

The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study.

Sferra R, Pompili S, Festuccia C, Marampon F, Gravina GL, Ventura L, Di Cesare E, Cicchinelli S, Gaudio E, Vetuschi A.

Eur J Histochem. 2017 May 16;61(2):2732. doi: 10.4081/ejh.2017.2732.

34.

The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.

Gravina GL, Mancini A, Colapietro A, Vitale F, Vetuschi A, Pompili S, Rossi G, Marampon F, Richardson PJ, Patient L, Patient L, Burbidge S, Festuccia C.

Tumour Biol. 2017 Jun;39(6):1010428317695528. doi: 10.1177/1010428317695528.

PMID:
28639900
35.

Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells.

Antinozzi C, Marampon F, Corinaldesi C, Vicini E, Sgrò P, Vannelli GB, Lenzi A, Crescioli C, Di Luigi L.

J Endocrinol Invest. 2017 Oct;40(10):1133-1143. doi: 10.1007/s40618-017-0686-y. Epub 2017 May 15.

36.

Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.

Gravina GL, Mancini A, Mattei C, Vitale F, Marampon F, Colapietro A, Rossi G, Ventura L, Vetuschi A, Di Cesare E, Fox JA, Festuccia C.

Oncotarget. 2017 May 2;8(18):29865-29886. doi: 10.18632/oncotarget.16168.

37.

HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.

Marampon F, Megiorni F, Camero S, Crescioli C, McDowell HP, Sferra R, Vetuschi A, Pompili S, Ventura L, De Felice F, Tombolini V, Dominici C, Maggio R, Festuccia C, Gravina GL.

Cancer Lett. 2017 Jul 1;397:1-11. doi: 10.1016/j.canlet.2017.03.028. Epub 2017 Mar 23.

PMID:
28342984
38.

Defective DNA repair mechanisms in prostate cancer: impact of olaparib.

De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C.

Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017. Review.

39.

The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs.

Rossi M, Fasciani I, Marampon F, Maggio R, Scarselli M.

Mol Pharmacol. 2017 Jun;91(6):586-594. doi: 10.1124/mol.116.107607. Epub 2017 Mar 6. Review.

40.

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.

Gravina GL, Mancini A, Marampon F, Colapietro A, Delle Monache S, Sferra R, Vitale F, Richardson PJ, Patient L, Burbidge S, Festuccia C.

J Hematol Oncol. 2017 Jan 5;10(1):5. doi: 10.1186/s13045-016-0377-8.

41.

Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.

Marampon F, Gravina GL, Ju X, Vetuschi A, Sferra R, Casimiro MC, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Sep 27;7(39):64526. doi: 10.18632/oncotarget.12267. No abstract available.

42.

DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.

Megiorni F, Camero S, Ceccarelli S, McDowell HP, Mannarino O, Marampon F, Pizer B, Shukla R, Pizzuti A, Marchese C, Clerico A, Dominici C.

Oncotarget. 2016 Nov 29;7(48):79342-79356. doi: 10.18632/oncotarget.12688.

43.

Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results.

De Felice F, Musio D, Gravina GL, Marampon F, Tombolini V.

Oncotarget. 2016 Nov 29;7(48):80077-80082. doi: 10.18632/oncotarget.11374.

44.

Increased expression and activity of p75NTR are crucial events in azacitidine-induced cell death in prostate cancer.

Gravina GL, Marampon F, Sanità P, Mancini A, Colapietro A, Scarsella L, Jitariuc A, Biordi L, Ficorella C, Festuccia C.

Oncol Rep. 2016 Jul;36(1):125-30. doi: 10.3892/or.2016.4832. Epub 2016 May 23.

PMID:
27222100
45.

c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.

Gravina GL, Festuccia C, Popov VM, Di Rocco A, Colapietro A, Sanità P, Monache SD, Musio D, De Felice F, Di Cesare E, Tombolini V, Marampon F.

Radiat Res. 2016 Apr;185(4):411-22. doi: 10.1667/RR14237.1.

PMID:
27104757
46.

Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: A retrospective study by propensity analysis.

Zugaro L, DI Staso M, Gravina GL, Bonfili P, Gregori L, Franzese P, Marampon F, Tombolini V, DI Cesare E, Masciocchi C.

Oncol Lett. 2016 Mar;11(3):1948-1954. Epub 2016 Jan 14.

47.

Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.

Ciccarelli C, Vulcano F, Milazzo L, Gravina GL, Marampon F, Macioce G, Giampaolo A, Tombolini V, Di Paolo V, Hassan HJ, Zani BM.

Mol Cancer. 2016 Feb 20;15:16. doi: 10.1186/s12943-016-0501-y.

48.

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models.

Gravina GL, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L, Landesman Y, McCauley D, Kauffman M, Shacham S, Festuccia C.

BMC Cancer. 2016 Jan 11;16:8. doi: 10.1186/s12885-015-2046-7. No abstract available.

49.

Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.

Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Feb 2;7(5):5383-400. doi: 10.18632/oncotarget.6579. Erratum in: Oncotarget. 2016 Sep 27;7(39):64526.

50.

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.

Gravina GL, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L, Landesman Y, McCauley D, Kauffman M, Shacham S, Festuccia C.

BMC Cancer. 2015 Dec 1;15:941. doi: 10.1186/s12885-015-1936-z. Erratum in: BMC Cancer. 2016;16:8.

Supplemental Content

Loading ...
Support Center